Drug Trial Radar · NCT00036270
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Last checked: Nov 19, 2026Latest source record: Oct 28, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,779
Actual
Start
Aug 2001
Primary completion
Oct 2008
Study completion Feb 2011
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 9, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer. This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.
Conditions
- Breast Neoplasms
Interventions
exemestane (Aromasin)Drug
exemestane, orally, 25 mg, for 5 years
tamoxifen + exemestaneDrug
tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 YearsTime frame: Baseline (Month 0) up to 2.75 years
- Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 5 YearsTime frame: Baseline (Month 0) up to 5 years
Locations
179 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Bessemer, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Flagstaff, Arizona
Pfizer Investigational Site
Green Valley, Arizona
Pfizer Investigational Site
Oro Valley, Arizona
Pfizer Investigational Site
Phoenix, Arizona
Pfizer Investigational Site
Safford, Arizona
Pfizer Investigational Site
Scottsdale, Arizona
Pfizer Investigational Site
Sedona, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Tuscon, Arizona
Pfizer Investigational Site
North Little Rock, Arkansas
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
Boulder, Colorado
Pfizer Investigational Site
Colorado Springs, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Fort Collins, Colorado
Pfizer Investigational Site
Lakewood, Colorado
Pfizer Investigational Site
Lone Tree, Colorado
Pfizer Investigational Site
Longmont, Colorado
Pfizer Investigational Site
Pueblo, Colorado
Pfizer Investigational Site
Thornton, Colorado
Pfizer Investigational Site
Clearwater, Florida
Pfizer Investigational Site
Hudson, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Lauderhill, Florida
Pfizer Investigational Site
Melbourne, Florida
Pfizer Investigational Site
New Port Richey, Florida
Pfizer Investigational Site
Ocala, Florida
Pfizer Investigational Site
Orange Park, Florida
Pfizer Investigational Site
Palatka, Florida
Pfizer Investigational Site
Plantation, Florida
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.